Skip to main content
Top
Published in: Clinical and Translational Oncology 1/2021

01-01-2021 | COVID-19 | Editorial

Low-dose radiation therapy: could it be a game-changer for COVID-19?

Authors: A. Montero, M. Arenas, M. Algara

Published in: Clinical and Translational Oncology | Issue 1/2021

Login to get access

Excerpt

At the beginning of December 2019, the first cases of a new acute respiratory syndrome, of extraordinary contagiousness, began to be described in the city of Wuhan, the capital of Hubei province, in central China. New virus, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) thus far unknown in the human species, was identified as the causative agent. Since then, humanity has witnessed a rapid spread of this RNA virus throughout the world, being recognized by the World Health Organization (WHO) as a pandemic on March 11, 2020. As of 12th April 2020, over 1 614,951 cases and nearly 100,000 deaths are reported worldwide [1]. The consequences of the coronavirus disease (COVID-19) have been quickly noticed, being Spain is one of the countries where the infection has shown the most virulence, putting our national health care system at an imaginable stress and with evident risk of collapse in case of uncontrolled outbreaks. …
Literature
2.
go back to reference Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J BiolRegul Homeost Agents. 2020. https://doi.org/10.23812/CONTI-E.CrossRef Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J BiolRegul Homeost Agents. 2020. https://​doi.​org/​10.​23812/​CONTI-E.CrossRef
3.
go back to reference Siddiqui HK, Mehra MR. Illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplantation COVID-19 Siddiqui HK, Mehra MR. Illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplantation COVID-19
7.
go back to reference Russell B, Moss C, George G, et al. Associations between immunosuppressive and stimulant drugs and the novel systematic review COVID-19-a of current evidence. Ecancermedical science. 2020;14:1022. Russell B, Moss C, George G, et al. Associations between immunosuppressive and stimulant drugs and the novel systematic review COVID-19-a of current evidence. Ecancermedical science. 2020;14:1022.
8.
go back to reference Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med. 2013;86(4):555–70.PubMedPubMedCentral Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med. 2013;86(4):555–70.PubMedPubMedCentral
9.
go back to reference Rödel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, Rödel C. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol. 2012;2:120.CrossRef Rödel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, Rödel C. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol. 2012;2:120.CrossRef
10.
go back to reference Arenas M, Sabater S, Hernández V, Rovirosa A, Lara PC, Biete A, Panés J. Anti-inflammatory effects of low-dose radiotherapy. Strahlenther Onkol. 2012;188(11):975–81.CrossRef Arenas M, Sabater S, Hernández V, Rovirosa A, Lara PC, Biete A, Panés J. Anti-inflammatory effects of low-dose radiotherapy. Strahlenther Onkol. 2012;188(11):975–81.CrossRef
11.
go back to reference Arenas M, Gil F, Gironella M, Hernández V, Biete A, Piqué JM, Panés J. Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol. 2008;86(3):399–406 Epub 2007 Nov 26.CrossRef Arenas M, Gil F, Gironella M, Hernández V, Biete A, Piqué JM, Panés J. Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol. 2008;86(3):399–406 Epub 2007 Nov 26.CrossRef
12.
go back to reference Lödermann B, Wunderlich R, Frey S, Schorn C, Stangl S, Rödel F, Keilholz L, Fietkau R, Gaipl US, Frey B. Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol. 2012;88(10):727–34.CrossRef Lödermann B, Wunderlich R, Frey S, Schorn C, Stangl S, Rödel F, Keilholz L, Fietkau R, Gaipl US, Frey B. Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol. 2012;88(10):727–34.CrossRef
15.
go back to reference Jansen JTM, Broerse JJ, Zoetelief J, Klein C, Seegenschmiedt HM. Estimation of the carcinogenic risk of radiotherapy of benign diseases from shoulder to heel. Radiother Oncol. 2005;76(3):270–7.CrossRef Jansen JTM, Broerse JJ, Zoetelief J, Klein C, Seegenschmiedt HM. Estimation of the carcinogenic risk of radiotherapy of benign diseases from shoulder to heel. Radiother Oncol. 2005;76(3):270–7.CrossRef
16.
go back to reference Trott KR, Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. Strahlenther Onkol. 2006;182(8):431–6.CrossRef Trott KR, Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. Strahlenther Onkol. 2006;182(8):431–6.CrossRef
17.
go back to reference Mazonakis M, Damilakis J. Cancer risk after radiotherapy for benign diseases. Phys Med Eur J Med Phys. 2017;42:285–91. Mazonakis M, Damilakis J. Cancer risk after radiotherapy for benign diseases. Phys Med Eur J Med Phys. 2017;42:285–91.
18.
go back to reference Trott MR, McKeown SR, Hatfield P, Prestwich RJD, Shaffer RE. Taylor RE Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol. 2015;88:20150405.CrossRef Trott MR, McKeown SR, Hatfield P, Prestwich RJD, Shaffer RE. Taylor RE Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol. 2015;88:20150405.CrossRef
Metadata
Title
Low-dose radiation therapy: could it be a game-changer for COVID-19?
Authors
A. Montero
M. Arenas
M. Algara
Publication date
01-01-2021
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2021
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02401-y

Other articles of this Issue 1/2021

Clinical and Translational Oncology 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine